Seres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of ($0.46), $0.04 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $13.02 million versus the consensus estimate of $10.38 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.